Abstract: The present invention generally relates to the field of heterologous protein production in host cells. In particular, the invention relates to a chemolithoautotrophic bacterium which has been genetically modified to produce one or more heterologous proteins. The invention also relates to a method for heterologous protein expression which makes use of the genetically modified chemolithoautotrophic bacterium of the invention. The invention further relates to the use of the genetically modified chemolithoautotrophic bacterium of the invention for heterologous protein expression. The invention also provides a kit which comprises the genetically modified chemolithoautotrophic bacterium of the invention. Finally, the invention relates to a method of introducing an exogenous nucleic acid molecule into a chemolithoautotrophic bacterium.

Abstract: The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.

Abstract: The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.

Abstract: The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.

Abstract: Anti-human interleukin 3 (IL-3) antibodies or fragments thereof according to the present invention are useful as therapeutic agents. The antibodies can be used in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated expression or levels of human IL-3 in a patient, especially inflammatory or autoimmune diseases, such as rheumatoid arthritis. The antibodies can also be used to detect human IL-3 expressed by human cells.

Abstract: Disclosed herein are information capture systems and related methods. An information capture system includes a sensor secured to an object configured to be involved with a possible event. The sensor is configured to detect one or more stimuli that are associated with the possible event, and transmit a sensor signal indicating data corresponding to the one or more stimuli. The information capture system also includes a recording device configured to record information responsive to a triggering event determined from the sensor signal. A method includes analyzing sensor data from the sensor, determining, from the sensor data, that a triggering event occurred, and recording post-trigger information following the determination of the triggering event.

Abstract: Anti-human IL-3 antibodies or fragments thereof according to the present invention are useful as therapeutic agents. The antibodies can be used in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated expression or levels of hIL-3 in a patient, especially inflammatory or autoimmune diseases, such as rheumatoid arthritis. The antibodies can also be used to detect human IL-3 expressed by human cells.

Abstract: Disclosed herein are information capture systems and related methods. An information capture system includes a sensor secured to an object configured to be involved with a possible event. The sensor is configured to detect one or more stimuli that are associated with the possible event, and transmit a sensor signal indicating data corresponding to the one or more stimuli. The information capture system also includes a recording device configured to record information responsive to a triggering event determined from the sensor signal. A method includes analyzing sensor data from the sensor, determining, from the sensor data, that a triggering event occurred, and recording post-trigger information following the determination of the triggering event.

Abstract: Disclosed herein are information capture systems and related methods. An information capture system includes a sensor secured to an object configured to be involved with a possible event. The sensor is configured to detect one or more stimuli that are associated with the possible event, and transmit a sensor signal indicating data corresponding to the one or more stimuli. The information capture system also includes a recording device configured to record information responsive to a triggering event determined from the sensor signal. A method includes analyzing sensor data from the sensor, determining, from the sensor data, that a triggering event occurred, and recording post-trigger information following the determination of the triggering event.

Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.

Abstract: Novel anti-interleukin 3 (IL-3) antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN (SEQ ID NO: 2). The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.

Abstract: A self-propelled, self-steering floor cleaning appliance is provided with at least one cleaning element for cleaning a floor surface, including a drive device having an undercarriage, a sensing part for sensing obstacles, at least one displaceable holding part for holding the sensing part on the floor cleaning appliance and at least one detection element for detecting a displacement of the at least one holding part and for providing a signal relating thereto. The floor cleaning appliance includes at least one accommodating part on which the at least one holding part is held so as to be displaceable in a first and a second direction of displacement, which is aligned at an angle to the first direction of displacement, and the at least one detection element is actuatable by the at least one holding part upon displacement of the holding part in the first and in the second directions of displacement.

Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.

Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.

Abstract: Disclosed herein are information capture systems and related methods. An information capture system includes a sensor secured to an object configured to be involved with a possible event. The sensor is configured to detect one or more stimuli that are associated with the possible event, and transmit a sensor signal indicating data corresponding to the one or more stimuli. The information capture system also includes a recording device configured to record information responsive to a triggering event determined from the sensor signal. A method includes analyzing sensor data from the sensor, determining, from the sensor data, that a triggering event occurred, and recording post-trigger information following the determination of the triggering event.

Abstract: The present invention relates to anti-IL-3 antibodies or IL-3 binding fragments thereof for use in the treatment of an autoimmune disease selected from the group consisting of systemic lupus erythematosus and multiple sclerosis, and to pharmaceutical compositions comprising such an antibody or antibody fragment.

Abstract: A self-propelled, self-steering floor cleaning appliance is provided with at least one cleaning element for cleaning a floor surface, including a drive device having an undercarriage, a sensing part for sensing obstacles, at least one displaceable holding part for holding the sensing part on the floor cleaning appliance and at least one detection element for detecting a displacement of the at least one holding part and for providing a signal relating thereto. The floor cleaning appliance includes at least one accommodating part on which the at least one holding part is held so as to be displaceable in a first and a second direction of displacement, which is aligned at an angle to the first direction of displacement, and the at least one detection element is actuatable by the at least one holding part upon displacement of the holding part in the first and in the second directions of displacement.

Abstract: For determining the presence and amount of human IL-3 in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3- antibody, fr agment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necesary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.

Abstract: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.

Abstract: Novel anti-IL-3 antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN. The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.